Dementia and Alzheimer Disease

The director of the Memory Disorders Program and professor of neurology at Georgetown University Medical Center details his findings from the phase 2 study of nilotinib in patients with Alzheimer disease.

The postdoctoral fellow at the University of Miami Miller School of Medicine detailed her study presented at AAIC 2020 that examined Alzheimer risk associated with APOE ε4 in different genetic populations.

Neurology News Network for the week ending August 1, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jeffrey Cummings, MD, ScD.

Multiple studies presented at AAIC 2020 highlight and confirm previous hypotheses of the role that early life cardiovascular risk factors play for individuals who develop late life dementia.

The data suggests that a planned multiple ascending dose study and a phase 2a proof-of-concept study in patients with mild cognitive impairment could be on the way.

Results presented virtually at AAIC 2020 support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.

Compared to treatment with lisinopril, those treated with the angiotensin receptor blocker candesartan showed improvements on the Trial Making Test part A and B and Hopkins Verbal Learning Test-Revised delayed recall.

Additional data presented at AAIC 2020 shows the clinical benefit pimavanserin has on dementia-related psychosis while the agent awaits a PDUFA date of April 3, 2021.

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada­–Las Vegas gives his thoughts on the latest aducanumab update and its potential as a treatment for Alzheimer disease.

Despite a lack of effect on memory and other cognitive tasks, as measured by ADAS-Cog-11, rotigotine improved frontal cognitive function and activities of daily living in those with Alzheimer.

The performance of p-tau217 was similar to significantly more costly methods, such as PET imaging and measuring cerebrospinal fluid biomarkers.

A trio of studies presented at AAIC 2020 suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.

Join NeurologyLive and the Women Neurologist Group on Twitter to discuss the importance of mental health and wellness in neurologic disorders.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 24, 2020.

The director emeritus of the Lou Ruvo Center for Brain Health at Cleveland Clinic and vice chair of the Department of Brain Health at the University of Nevada-Las Vegas, details trends in Alzheimer disease research over the past few years.

The assistant professor of neurosurgery at Yale School of Medicine discussed what doors have been opened by a recent study of the cell death process she and colleagues conducted.

The regulatory agency has set prescription drug user fee act action date of April 3, 2021, for the Acadia Pharmaceuticals product.

As of February of this year, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.

Neurology News Network for the week ending July 18, 2020.

Neurology News Network for the week ending July 18, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 17, 2020.

The assistant professor of neurosurgery at Yale School of Medicine discussed the work that still needs to be done to understand the role cell death process might play in neurodegeneration as the human body ages.

The assistant professor of neurosurgery at Yale School of Medicine discussed the observations she and colleagues have made of the relationship between microglia and astrocytes in the cell death process.